Nishith Amin, MD
Interventional Cardiology · Camillus, NYNPI 1336136860
Payments from drug & device makers
Across 133 payments — averaging $24.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$334
- Amgen$321
- AstraZeneca$229
- Abiomed$218
- Cardiovascular Systems Inc.$217
- Merck$214
- plus $2K from 29 others
What the payments were for
- Food & beverage$3,26599%
- Education$221%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 20 | $334 |
| Amgen | 21 | $321 |
| AstraZeneca | 8 | $229 |
| Abiomed | 5 | $218 |
| Cardiovascular Systems Inc. | 3 | $217 |
| Merck | 8 | $214 |
| Medtronic | 7 | $210 |
| Edwards Lifesciences | 5 | $166 |
| Novo Nordisk | 8 | $165 |
| Lilly USA, LLC | 2 | $146 |
| Biotronik Inc. | 3 | $137 |
| EKOS Corporation | 1 | $135 |
| Inari Medical, Inc. | 1 | $85 |
| Corcept Therapeutics | 3 | $77 |
| Teva Pharmaceuticals USA, Inc. | 4 | $67 |
| Boehringer Ingelheim | 3 | $55 |
| Pfizer | 3 | $45 |
| Inspire Medical Systems, Inc. | 2 | $44 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $43 |
| Kiniksa Pharmaceuticals, Ltd. | 2 | $42 |
| Bayer | 2 | $39 |
| Regeneron Healthcare Solutions, Inc. | 3 | $37 |
| Lexicon Pharmaceuticals, Inc. | 2 | $34 |
| Johnson & Johnson | 2 | $28 |
| E.r. Squibb & Sons, L.L.C. | 2 | $26 |
| Abbott | 1 | $24 |
| Penumbra, Inc. | 2 | $24 |
| Insulet Corporation | 1 | $23 |
| AbbVie | 1 | $22 |
| Amarin Pharma, Inc. | 1 | $16 |
| Collegium Pharmaceutical, Inc. | 1 | $14 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $14 |
| Celonova Biosciences, Inc. | 1 | $13 |
| Gilead | 1 | $12 |
| Boston Scientific | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,287 in reported general payments places this provider in the 20th percentile of 382 interventional cardiology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 186 | $218,293 |
| JardianceEmpagliflozin | 130 | $106,958 |
| FarxigaDapagliflozin Propanediol | 49 | $45,690 |
| EntrestoSacubitril/Valsartan | 34 | $41,849 |
| XareltoRivaroxaban | 21 | $33,652 |
| Repatha SureclickEvolocumab | 15 | $15,947 |
| VascepaIcosapent Ethyl | 19 | $12,415 |
| Metoprolol Succinate | 263 | $3,408 |
| Atorvastatin Calcium | 227 | $2,333 |
| Ezetimibe | 126 | $2,224 |
| Ranolazine ErRanolazine | 27 | $2,082 |
| Irbesartan | 24 | $1,132 |
| Rosuvastatin Calcium | 77 | $1,074 |
| Amiodarone Hcl | 57 | $820 |
| Losartan Potassium | 80 | $740 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $45 | $218,293186 claims |
| Boehringer IngelheimJardiance | $55 | $106,958130 claims |
| AstraZenecaFarxiga | $229 | $45,69049 claims |
| NovartisEntresto | $334 | $41,84934 claims |
| Johnson & JohnsonXarelto | $28 | $33,65221 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 382 interventional cardiology providers in New York.
Other interventional cardiology in Camillus
- Martin LeonNew York$13.5M
- David CohenRoslyn$9.8M
- Susheel KodaliNew York$6M
- Mohamed Azeem LatibBronx$4.6M
- Richard ShlofmitzRoslyn$4.5M
- Deepak BhattNew York$4.1M
- Samin SharmaNew York$3.7M
- Annapoorna KiniNew York$3.5M
- Sahil ParikhNew York$2.7M
- George DangasNew York$2.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.